Clinical trials: Child Disruptive Behavior Disorders
Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning…
- Trial name
- NCT02096952
- Testing
- Methylphenidate extended-release liquid formulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
ADHD
Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication
The purpose of this study is to see if supplementing calories with Pediasure is effective in maintaining height, weight, and BMI percentiles for young children during 2 years of treatment with ADHD medication.
- Trial name
- NCT00561340
- Testing
- Pediasure, Nutritional counseling
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Nebraska
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Omega-3 Supplementation to ADHD Medication in Children
This study is a 12-week open-label trial to assess the effectiveness of Omega-3 fatty acids for deficient emotional self-regulation (DESR) as a supplement to Attention Deficit/Hyperactivity Disorder (ADHD) treatment in children…
- Trial name
- NCT02204410
- Testing
- Omega-3 Fatty Acid, ADHD Medication
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
ADHD - Inattentive Type, ADHD - Combined Type
Attention Deficit Disorder Medication Response Study
This study evaluates how children with Attention Deficit Disorder without Hyperactivity (ADD) respond to medication, and if their response is different from children who have problems with both hyperactivity and inattention.
- Trial name
- NCT01727414
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder
Cognitive ADHD Videogame Exploratory Study
A study in ADHD and neuro-typical children to assess EVO game play over 29 days.
- Trial name
- CAVES (NCT01943539)
- Testing
- Neuro-typical controls and ADHD will receive EVO game play.
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Disorder With Hyperactivity, Behavioral Insomnia of Childhood
Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD
Over 10% of children in the United States are diagnosed with ADHD, and nearly half of these children have moderate to severe impairments in sleep, further exacerbating their already impaired academic, emotional and social…
- Trial name
- NCT02638168
- Testing
- Immediate Release Methylphenidate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Milton S. Hershey Medical Center
ADHD, Attention Deficit Hyperactivity Disorder
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
Organizational, time management and planning (OTMP) skills deficits are impairing features of developmental disorders, such as Attention Deficit Hyperactive Disorder (ADHD), which compromise school performance and family…
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, Neurodevelopmental Disorders
- Trial name
- NCT04108273
- Testing
- Organizational Skills Training
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- NYU Langone Health
Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
The primary objective of this study was to evaluate the efficacy and safety of Mexidol® film-coated tablets (125 mg) compared to a placebo in children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- MEGA (NCT06854601)
- Testing
- Mexidol
- Where
- 14 sites in Russia
- Volunteers
- 333 people
- Sponsor
- Pharmasoft
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
- Trial name
- NCT03325881
- Testing
- SHP465
- Where
- 41 sites in United States
- Volunteers
- 89 people
- Sponsor
- Shire
Attention-Deficit/Hyperactivity Disorder (ADHD)
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- ADHD (NCT04786990)
- Testing
- SPN-812
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 96 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD
This study looks to examine whether or not INTUNIV extended release can help children aged 6-12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) in improving Executive Function when added to their usual care…
- Trial name
- NCT01985581
- Testing
- Guanfacine extended release, Stimulant therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- JPM van Stralen Medicine Professional
Attention Deficit Hyperactivity Disorder
Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
Purpose of the study: evaluate the efficacy and safety of Prospekta in the treatment of attention deficit/hyperactivity disorder in children.
- Trial name
- NCT04569357
- Testing
- Prospekta
- Where
- 31 sites in Russia
- Volunteers
- 363 people
- Sponsor
- Materia Medica Holding
Conduct Disorder, Conduct Disorders in Children
Impact VR: An Emotion Recognition and Regulation Training Program for Youth With CD
Conduct disorder (CD) is one of the most prevalent childhood psychiatric disorders. Unfortunately, there are limited treatments available for CD.
- Conditions
- Conduct Disorder, Conduct Disorders in Children, Conduct Disorders in Adolescence, Callous-Unemotional Traits
- Trial name
- NCT06301516
- Testing
- Virtual Reality, Comparative Control
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Virginia Commonwealth University
Attention Deficit Hyperactivity Disorder, INSOMNIA
Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD
Methylphenidate may improve sleep in children with ADHD. By leaving Daytrana (methylphenidate) patch for a longer time then 9 hours, many children report short sleep latencies and better quality of sleep.
- Trial name
- Daytsleep (NCT00989950)
- Testing
- Daytrana
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Cox Health Systems
Attention-Deficit Hyperactivity Disorder
Pharmacokinetics of HLD200 in Children and Adolescents With ADHD
This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.
- Trial name
- NCT01907360
- Testing
- HLD200 (methylphenidate hydrochloride)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Attention Deficit/Hyperactivity Disorder
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
This is a multicenter, dose-optimized, randomized, double-blind, placebo controlled, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P01 (NCT05685732)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 246 people
- Sponsor
- Corium, Inc.
Attention Deficit Disorder With Hyperactivity
Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood
This study will evaluate the effectiveness of an integrative group psychosocial therapy combined with stimulant medication in treating children with attention deficit hyperactivity disorder plus impairments in mood.
- Trial name
- NCT00632619
- Testing
- Group-based behavior therapy, Stimulant medication therapy, Community-based psychosocial treatment
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Florida International University
Autistic Disorder, Attention Deficit Disorder With Hyperactivity
Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).
- Trial name
- NCT00380692
- Testing
- Atomoxetine
- Where
- 8 sites in Netherlands
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder Symptoms
Implementation Strategy Resource Package for Behavioral Classroom Interventions: Pilot Test
The purpose of this study is to pilot test for feasibility and initial promise an implementation strategy resource package that aims to support teachers in using behavioral classroom management interventions for children with…
- Trial name
- NCT05489081
- Testing
- Positive Behavior Management Toolkit
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Alzheimer's Disease, Disruptive Behavior
Prazosin for Agitation in Alzheimer's Disease
The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion
- Trial name
- NCT03710642
- Testing
- Prazosin
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)